Pharmerit (Netherlands)

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 10 of 34 papers

  • Open Access
  • Research Article
  • Citations2

Challenges and opportunities of adding CFTR modulators for cystic fibrosis to the WHO essential medicines list.

  • Sep 01, 2025
  • Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
  • Enrico Costa +2
  • Open Access
  • Abstract

MSR58 Relating Heterotopic Ossification Volume to Joint Function And Quality of Life: A Simulation Study in Fibrodysplasia Ossificans Progressiva (FOP)

  • Jun 01, 2023
  • Value in Health
  • L Verburg - Baltussen +5
  • Open Access
  • PDF
  • Research Article
  • Citations23

A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France.

  • Jun 10, 2021
  • PloS one
  • Kaspar Nieland +7
  • Open Access
  • Research Article
  • Citations1

PCN42 Real-World Effectiveness in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma – a Systematic Literature Review Update

  • Dec 01, 2020
  • Value in Health
  • A.m Trip +8
  • Open Access
  • Abstract

PCN301 Reported Utilities for Patients with Previously Untreated Advanced/Metastatic Renal Cell Carcinoma - a Systematic Literature Review Update

  • Dec 01, 2020
  • Value in Health
  • O Zaidi +7
  • Open Access
  • Research Article
  • Citations48

Real‐world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome

  • Jun 04, 2020
  • Alimentary Pharmacology & Therapeutics
  • Kevin Moore +12
  • Open Access
  • Research Article
  • Citations1

Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US.

  • Jan 21, 2020
  • Journal of comparative effectiveness research
  • Arshad M Khanani +6
  • Abstract
  • Citations1

PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE

  • Nov 01, 2019
  • Value in Health
  • S Branchoux +8
  • Open Access
  • Abstract

PCN347 COMPARISON OF TIME TO REIMBURSEMENT RECOMMENDATIONS OF (ORPHAN-) ONCOLOGY DRUGS IN EUROPE

  • Nov 01, 2019
  • Value in Health
  • L Nientker +2
  • Open Access
  • PDF
  • Research Article
  • Citations89

The economic burden of bronchiectasis \u2013 known and unknown: a systematic review

  • Feb 28, 2019
  • BMC Pulmonary Medicine
  • Pieter C Goeminne +10
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.